share_log

NeuroSense Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Alon Ben-Noon(19.98%)

SEC ·  Feb 13 23:19

Summary by Futu AI

Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated